Cancer Therapies
VERAXA Biotech Begins Trading on Nasdaq After Completing Business Combination
VERAXA Biotech AG, formed through a merger with Voyager Acquisition Corp., starts trading on Nasdaq under ticker VRXA, advancing its BiTAC platform for cancer therapies with new financing.
ABVC BioPharma Receives Additional $100,000 Payment from OncoX, Strengthening Licensing Revenue Strategy
ABVC BioPharma's continued licensing payments from OncoX BioPharma demonstrate the successful execution of its asset-light business model and highlight the growing value of plant-based cancer therapies in the biopharmaceutical market.
Calidi Biotherapeutics Secures $6.9 Million in Public Offering to Advance Targeted Cancer Therapies
Calidi Biotherapeutics has closed a $6.9 million public offering, providing crucial funding to advance its clinical-stage targeted therapies for delivering genetic medicines to metastatic cancer sites.
CNS Pharmaceuticals Inc. Showcases Lead Cancer Treatment Program in Virtual CEO Segment
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) emphasizes its lead cancer treatment program during a virtual CEO segment, highlighting potential advancements in brain and central nervous system cancer therapies.
VERAXA Biotech AG and Voyager Acquisition Corp. Announce $1.64 Billion Merger to Advance Cancer Therapies
VERAXA Biotech AG and Voyager Acquisition Corp. have agreed to a $1.64 billion merger, aiming to accelerate the development of innovative cancer therapies through VERAXA's Bi-Targeted Antibody Cytotoxicity platform.